SENS announcement for JSE listed company: APN
BACK TO SENS

ASPEN PHARMACARE HOLDINGS LIMITED – Trading Statement

  Download PDF
  PRINT   Sens history   Click this Company   Company News

                            

Trading Statement

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen” or “the Group”)

TRADING STATEMENT

This trading statement is provided to the shareholders of Aspen Holdings as guidance on the key
performance metrics relating to the results of the Group for the six months ended 31 December 2020,
expected to be published on SENS on 11 March 2021, after market close.

The outcome achieved has been delivered despite the ongoing challenges imposed by COVID-19 and is
testimony to the resilience and agility of our teams that have ensured Aspen has been able to make a
meaningful contribution to the fight against the pandemic.

• Revenue growth from continuing operations as reported, and in constant exchange rates (“CER”),
is expected to be within the following ranges:

• 16% to 18% (5% to 7% CER)

The difference between reported and CER revenue growth is a result of the weakening of the ZAR
against the majority of the other currencies in which Aspen trades.

• Reported continuing operations revenue from Commercial Pharmaceuticals is expected to increase
by between 11% and 13% (3% and 5% CER), supported by growth in all regions. Manufacturing has
delivered impressive double-digit revenue growth, both as reported and in CER. Finished dose
form, API-Chemicals and API-Biochem Manufacturing segments all performed strongly.

• Net borrowings have declined to approximately ZAR 28 billion at 31 December 2020 from ZAR 35
billion at 30 June 2020. The reduction in net borrowings was supported by the upfront cash
consideration from the completion of the divestment of the European Thrombosis Business and
the strengthening of the ZAR relative to the EUR and AUD which deflated the ZAR value of Aspen’s
debt denominated in those currencies. The outstanding consideration for the European
Thrombosis Business, amounting to ZAR 7.0 billion(1), is receivable before the end of June 2021.

• The leverage ratio(2), for banking covenant measurement purposes, as at 31 December 2020, is
expected to be between 2.80x and 2.85x against a threshold of 3.50x. This is in line with our
commitment to maintain a stable balance sheet with a leverage ratio no greater than 3.0x.

• Discontinued operations for the six months ended 31 December 2020 comprises the results of the
European Thrombosis Business to date of disposal (being 27 November 2020), the costs relating to
its disposal, related Thrombosis product discontinuations and the residual costs related to prior
period disposals. Discontinued operations in the prior period includes the results of the operations
classified as discontinued in the current period as well as those discontinued in the prior financial
year.

Earnings measures

Normalised headline earnings per share (“NHEPS”) comprises headline earnings per share adjusted for
specific non-trading items in accordance with Aspen’s accounting policies. NHEPS is the primary measure
used by management to assess Aspen’s underlying financial performance.

Continuing earnings measures for the six months ended 31 December 2020 are expected to vary from
those reported in the prior restated six months ended 31 December 2019 within the ranges set out in
the table below. The following influences should be noted:

• Headline earnings per share – Continuing has been diluted by increased restructuring costs in the
current period; and
• Earnings per share – Continuing has benefitted from lower impairment charges in the current
period.

Continuing operations

Earnings measures Range (%) Range (Cents per share) Cents per share –
– 31 December 2020
31 December 2019
(Restated) *

NHEPS – Continuing 13% to 18% 661.2 to 690.4 585.1 *

Headline earnings per share – 8% to 13% 557.0 to 582.7 515.7 *
Continuing

Earnings per share – Continuing 18% to 23% 484.7 to 505.3 410.8 *

* The results for the six months ended 31 December 2019 have been restated to exclude the operations
discontinued in the six months ended 31 December 2020. The impact of this restatement has been a decrease of
122 cents across all continuing earnings measures

Total earnings measures for the six months ended 31 December 2020 are expected to vary from those
reported in the prior six months ended 31 December 2019 within the ranges set out in the table below.
In addition to the factors related to continuing operations covered above, the ranges reported below
are influenced by the inclusion of discontinued operations. The material discontinued operations are:

• The Japanese Business and the fludrocortisone product, both of which were disposed in the second
half of the prior financial year;
• The European Thrombosis Business and related discontinuations which became effective in
November 2020.

Operations, including discontinued operations (3)

Earnings measures Range (%) Range (Cents per share) Cents per share –
– 31 December 2020
31 December 2019

Total NHEPS -11% to -6% 676.0 to 714.0 759.6

Total Headline earnings per -21% to -16% 544.9 to 579.3 689.7
share

Total Earnings per share -6% to -1% 541.4 to 570.2 576.0

Notes
(1) EUR 389 million at Aspen’s closing exchange rate of ZAR 17.91 to EUR 1
(2) Calculated in terms of the Facilities Agreement
(3) Operations include continuing and discontinued operations

The financial results on which this trading statement is based have not been reviewed or reported on by
Aspen’s external auditors.

Durban
23 February 2021

Sponsor
Investec Bank Limited

Date: 23-02-2021 05:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited (‘JSE’).
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.


  Download PDF
  PRINT   Sens history   Click this Company   Company News
BACK TO SENS
INSIDER SUBSCRIPTIONS APP VIDEOS RADIO / PODCASTS SHOP OFFERS WEBINARS NEWSLETTERS TRENDING PORTFOLIO TOOL CPD HUB

Follow us:

Search Articles: Advanced Search
Click a Company: